Seminari di Ematologia Oncologica - Società Italiana di Ematologia

Borchmann P, Viardot A, et al. Aggressive chemotherapy
(CHOEP-14) and Rituximab or High-Dose Therapy
(MegaCHOEP) and Rituximab for young, high-risk
patients with aggressive B-cell lymphoma: results of
the MegaCHOEP trial of the German High-Grade Non-
Hodgkin Lymphoma Study Group (DSHNHL). Blood.
2009; 114: 404.
24. Milpied NJ, Legouill S, Lamy T, Delwail V, Gressin R,
Guyotat D, et al. No benefit of first-line Rituximab (R)
- High-Dose Therapy (R-HDT) over R-CHOP14 for
young adults with Diffuse Large B-Cell Lymphoma.
Preliminary results of the GOELAMS 075 prospective
multicentre randomized trial. Blood. 2010; 116: 685.
25. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi
G. A comprehensive geriatric assessment is more effective
than clinical judgment to identify elderly diffuse large
cell lymphoma patients who benefit from aggressive
therapy. Cancer. 2009; 115: 4547-53.
26. Pfreundschuh M. How I treat elderly patients with diffuse
large B-cell lymphoma. Blood. 2010; 116: 5103-10.
27. Delarue R, Tilly H, Salles G, Gisselbrecht C, Mounier
N, Fournier M, et al. R-CHOP14 Compared to R-
CHOP21 in Elderly Patients with Diffuse Large B-Cell
Lymphoma: Results of the Interim Analysis of the
LNH03-6B GELA Study. Blood. 2009; 114: 406.
28. Cunningham D, Smith P, Mouncey P, et al. A phase III
trial comparing R-CHOP 14 and R-CHOP 21 for the
treatment of patients with newly diagnosed diffuse large
B-cell non-Hodgkin’s lymphoma [Abstract]. J Clin Oncol.
2009; 27: 435s.
29. Pfreundschuh M, Zeynalova S, Poeschel V, et al.
Improved outcome of elderly patients with poor prognosis
diffuse large B-cell lymphoma (DLBCL) after
dose-dense Rituximab: results of the DENSE-R-
CHOP-14 trial of the German High-Grade Non-
Hodgkin Lymphoma Study Group (DSHNHL) [Abstract].
Ann Oncol 2008; 19 (Suppl 4): iv99.
30. Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted
treatment and new agents in diffuse large B-cell lymphoma.
[Abstract]. Semin Hematol. 2008; 45 (S2): 11-
16.
31. Vitolo U, Chiappella A, Carella AM, Baldi I, Ciccone G,
Congiu A, et al. Prospective, multicenter phase I-II pilot
trial to evaluate efficacy and safety of Lenalidomide plus
Rituximab-CHOP21 (LR-CHOP21) for elderly patients
with untreated Diffuse Large B-Cell Lymphoma (DLB-
CL): interim analysis of the Intergruppo Italiano Linfomi
(IIL) REAL07 study. Blood. 2010; 116: 2871.
32. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous
bone marrow transplantation as compared with salvage
chemotherapy in relapses of chemotherapy-sensitive
non-Hodgkin's lymphoma. N Engl J Med. 1995; 333:
1540-45.
33. Blay JY, Gomez F, Sebban C, et al. The international
prognostic index correlates to survival in patients with
aggressive lymphoma in relapse: analysis of the PAR-
MA trial. Blood. 1998; 92: 3562-68.
Linfomi non Hodgkin a grandi cellule
34. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli
M, Sebban C, et al. Time to relapse has prognostic value
in patients with aggressive lymphoma enrolled into
the Parma trial. J Clin Oncol. 1998; 16: 3264-19.
35. Gisselbrecht C, Glass B, Mounier N, Gill D, Linch
DC, Trneny M, et al. Salvage regimens with autologous
transplantation for relapsed large B-cell lymphoma
in the Rituximab era. J Clin Oncol. 2010; 28:
4184-90.
36. Spaepen K, Stroobants S, Dupont P, et al. Prognostic
value of positron emission tomography (PET) with fluorine-18
fluorodeoxyglucose ([18F]FDG) after first-line
chemotherapy in non-Hodgkin's lymphoma: is
[18F]FDG-PET a valid alternative to conventional diagnostic
methods? J Clin Oncol. 2001; 19: 414-19.
37. Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault
M, Brice P, et al. The impact of pre- and post-transplantation
positron emission tomography using 18-fluorodeoxyglucose
on poor-prognosis lymphoma
patients undergoing autologous stem cell transplantation.
Cancer. 2007; 110: 1361-69.
38. Vellenga E, Notenboom A, van’t Veer M, et al.
Rituximab (Mabthera) improves the treatment results
of DHAP-VIM-DHAP and ASCT in relapsed/progressive
aggressive CD20+ NHL. A prospective randomized
HOVON trial. Blood. 2008; 111: 537-43.
39. Thieblemont C, Briere J, Mounier N, et al. Prognostic
Impact of Germinal Center (GC)/ Activated B-Cell
(ABC) Classification Analysed by Immunochemistry,
FISH Analysis and GEP, In Relapsed/Refractory
Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-
CORAL Study. [Abstract]. Proc Am Soc Hematol.
2010; abstr 993.
40. Shimoni A, Zwas ST, Oksman Y, et al. Yttrium-90ibritumomab
tiuxetan (Zevalin) combined with highdose
BEAM chemotherapy and autologous stem cell
transplantation for chemo-refractory aggressive
non-Hodgkin's lymphoma. Exp Hematol. 2007; 35:
534-40.
41. Krishnan A, Nademanee A, Fung HC, Raubitschek AA,
Molina A, Yamauchi D, et al. Phase II trial of a transplantation
regimen of yttrium-90 ibritumomab tiuxetan
and high-dose chemotherapy in patients with non-
Hodgkin’s lymphoma. J Clin Oncol. 2008; 26: 90-5.
42. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen
F, Appelbaum F, De Vol E, Ernst P. Autologous versus
allogeneic bone marrow transplantation for non
Hodgkin’s lymphoma: a case-controlled analysis of the
European Bone Marrow Transplant Group Registry
data. J Clin Oncol 1992; 10: 1690-5.
43. Peniket A J, Ruiz de Elvira Peniket AJ, Ruiz de Elvira
MC, Taghipour G, Cordonnier C, Gluckman E, de Witte
T, Santini G, Blaise D, Greinix H, Ferrant A, Cornelissen
J, Schmitz N, Goldstone AH. An EBMT registry
matched study of allogeneic stem cell transplants for
lymphoma: allogeneic transplantation is associated with
a lower relapse rate but a higher procedure-related
27